News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
582,168 Results
Type
Article (39885)
Company Profile (99)
Press Release (542183)
Multimedia
Podcasts (110)
Webinars (17)
Section
Business (170604)
Career Advice (2040)
Deals (25453)
Drug Delivery (105)
Drug Development (71316)
Employer Resources (124)
FDA (14517)
Job Trends (12253)
News (286956)
Policy (26630)
Tag
Academia (2522)
Academic (2)
Accelerated approval (9)
Adcomms (20)
Allergies (87)
Alliances (44901)
ALS (106)
Alzheimer's disease (1355)
Antibody-drug conjugate (ADC) (156)
Approvals (14535)
Artificial intelligence (319)
Autoimmune disease (33)
Automation (16)
Bankruptcy (214)
Best Places to Work (9924)
BIOSECURE Act (21)
Biosimilars (100)
Biotechnology (68)
Bladder cancer (90)
Brain cancer (34)
Breast cancer (362)
Cancer (2798)
Cardiovascular disease (205)
Career advice (1712)
Career pathing (29)
CAR-T (180)
CDC (36)
Cell therapy (503)
Cervical cancer (22)
Clinical research (58938)
Collaboration (1032)
Company closure (1)
Compensation (421)
Complete response letters (21)
COVID-19 (2323)
CRISPR (55)
C-suite (317)
Cystic fibrosis (101)
Data (2960)
Decentralized trials (2)
Denatured (32)
Depression (52)
Diabetes (351)
Diagnostics (5357)
Digital health (23)
Diversity (7)
Diversity, equity & inclusion (40)
Drug discovery (145)
Drug pricing (124)
Drug shortages (32)
Duchenne muscular dystrophy (121)
Earnings (68708)
Editorial (47)
Employer branding (16)
Employer resources (112)
Events (89630)
Executive appointments (810)
FDA (16128)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (2)
Frontotemporal dementia (8)
Funding (872)
Gene editing (117)
Generative AI (31)
Gene therapy (373)
GLP-1 (842)
Government (3820)
Grass and pollen (5)
Guidances (180)
Healthcare (16539)
HIV (38)
Huntington's disease (24)
IgA nephropathy (35)
Immunology and inflammation (130)
Immuno-oncology (12)
Indications (40)
Infectious disease (2489)
Inflammatory bowel disease (143)
Inflation Reduction Act (11)
Influenza (61)
Intellectual property (110)
Interviews (370)
IPO (11613)
IRA (48)
Job creations (2723)
Job search strategy (1451)
Kidney cancer (7)
Labor market (41)
Layoffs (393)
Leadership (22)
Legal (6125)
Liver cancer (73)
Longevity (10)
Lung cancer (390)
Lymphoma (202)
Machine learning (8)
Management (41)
Manufacturing (385)
MASH (93)
Medical device (10914)
Medtech (10919)
Mergers & acquisitions (14523)
Metabolic disorders (880)
Multiple sclerosis (97)
NASH (17)
Neurodegenerative disease (111)
Neuropsychiatric disorders (27)
Neuroscience (1995)
NextGen: Class of 2025 (5608)
Non-profit (4197)
Now hiring (36)
Obesity (449)
Opinion (231)
Ovarian cancer (94)
Pain (99)
Pancreatic cancer (113)
Parkinson's disease (176)
Partnered (18)
Patents (274)
Patient recruitment (165)
Peanut (42)
People (49724)
Pharmaceutical (31)
Pharmacy benefit managers (16)
Phase I (18183)
Phase II (25709)
Phase III (19754)
Pipeline (1591)
Policy (214)
Postmarket research (2459)
Preclinical (7734)
Press Release (69)
Prostate cancer (144)
Psychedelics (32)
Radiopharmaceuticals (221)
Rare diseases (424)
Real estate (5112)
Recruiting (47)
Regulatory (19011)
Reports (37)
Research institute (2250)
Resumes & cover letters (312)
Rett syndrome (10)
RNA editing (8)
RSV (52)
Schizophrenia (82)
Series A (157)
Series B (96)
Service/supplier (7)
Sickle cell disease (57)
Special edition (17)
Spinal muscular atrophy (126)
Sponsored (28)
Startups (2844)
State (1)
Stomach cancer (12)
Supply chain (76)
Tariffs (58)
The Weekly (76)
Vaccines (758)
Venture capital (44)
Weight loss (307)
Women's health (37)
Worklife (16)
Date
Today (97)
Last 7 days (403)
Last 30 days (1577)
Last 365 days (28432)
2025 (16086)
2024 (30529)
2023 (33780)
2022 (44102)
2021 (46931)
2020 (45346)
2019 (39807)
2018 (29973)
2017 (27392)
2016 (26658)
2015 (30687)
2014 (24820)
2013 (21375)
2012 (22114)
2011 (22680)
2010 (21045)
Location
Africa (728)
Alabama (64)
Alaska (6)
Arizona (170)
Arkansas (11)
Asia (38844)
Australia (5297)
California (6646)
Canada (1978)
China (727)
Colorado (291)
Connecticut (313)
Delaware (192)
Europe (77347)
Florida (970)
Georgia (229)
Hawaii (2)
Idaho (41)
Illinois (590)
India (30)
Indiana (312)
Iowa (17)
Japan (225)
Kansas (87)
Kentucky (26)
Louisiana (15)
Maine (35)
Maryland (932)
Massachusetts (5059)
Michigan (220)
Minnesota (356)
Mississippi (2)
Missouri (72)
Montana (27)
Nebraska (20)
Nevada (69)
New Hampshire (50)
New Jersey (1968)
New Mexico (25)
New York (1904)
North Carolina (977)
North Dakota (10)
Northern California (2911)
Ohio (207)
Oklahoma (17)
Oregon (30)
Pennsylvania (1374)
Puerto Rico (11)
Rhode Island (36)
South America (1020)
South Carolina (31)
South Dakota (1)
Southern California (2530)
Tennessee (118)
Texas (1000)
United States (24757)
Utah (193)
Virginia (166)
Washington D.C. (71)
Washington State (556)
West Virginia (4)
Wisconsin (72)
582,168 Results for "novo nordisk china r and d center".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Weight loss
Novo Nordisk’s Termination of Hims & Hers Deal Reignites Compounding Row
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the “litigation risk is back on the table” now that the Danish pharma has stepped away.
July 9, 2025
·
4 min read
·
Annalee Armstrong
Tariffs
Novo Opposes Pharma Tariffs, Urges Crackdown on Illicit Chinese Semaglutide
In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, constitutes a national security threat to the U.S.
May 29, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
July 21, 2025
·
2 min read
GLP-1
EU Regulators Confirm Rare Vision Loss Risk for Novo’s Semaglutide
Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include the “very rare” risk of non-arteritic anterior ischemic optic neuropathy.
June 6, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
July 25, 2025
·
8 min read
Press Releases
Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
June 23, 2025
·
6 min read
Press Releases
NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery
June 11, 2025
·
6 min read
Podcast
Trump’s US Manufacturing Push, New Vaccine Policy, Novo’s Weight Loss Pill up for FDA Review
A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will require placebo-controlled trials for all vaccine approvals; tariff threats hit BioNTech; Novo Nordisk’s FDA application for an oral version of Wegovy is accepted; and more.
May 7, 2025
·
1 min read
·
Heather McKenzie
Press Releases
Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
June 26, 2025
·
12 min read
Obesity
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of safety, according to newly released comprehensive tolerability data—findings that Leerink analysts say confirm the GLP-1 drug’s edge in the closely watched market race.
May 12, 2025
·
2 min read
·
Tristan Manalac
1 of 58,217
Next
